Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Nanoscale|August 16, 2020
Low-threshold laser medium utilizing semiconductor nanoshell quantum dotsDmitry Porotnikov, Benjamin T Diroll, Dulanjan Harankahage, et al.
Clinical Colorectal Cancer|July 2, 2013
The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT databaseWinson Y Cheung, Qian Shi, Michael O'Connell, et al.
Cancer Chemotherapy and Pharmacology|February 4, 2014
Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trialCarlos R Becerra, Ramon Salazar, Rocio Garcia-Carbonero, et al.
Clinical Genetics|August 12, 2020
Homozygous TAF1C variants are associated with a novel childhood-onset neurological phenotypeOula Knuutinen, Angela Pyle, Maria Suo-Palosaari, et al.
ACS Nano|February 7, 2022
Quantum Shells Boost the Optical Gain of Lasing MediaJames Cassidy, Benjamin T Diroll, Navendu Mondal, et al.
Journal of the American Chemical Society|June 6, 2023
Quantum Shell in a Shell: Engineering Colloidal Nanocrystals for a High-Intensity Excitation RegimeDulanjan Harankahage, James Cassidy, Jacob Beavon, et al.
Nature|July 15, 2026
Ammonia pressure controls colloidal metal nitride synthesis in molten saltsRuiming Lin, Vikash Khokhar, Ningxin Jiang, et al.
International Journal of Oncology|May 9, 2009
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancerLeonard W Seymour, David R Ferry, David J Kerr, et al.
Radiation Oncology (London, England)|August 27, 2021
Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)Catherine R Hanna, Sean M O'Cathail, Janet S Graham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME studyJean-Yves Douillard, Salvatore Siena, James Cassidy, et al.
Pageof 6